Product
GD2-CAR-expressing Autologous T-lymphocytes
1 clinical trial
2 indications
Indication
NeuroblastomaIndication
OsteosarcomaClinical trial
GD2-CAR PERSIST: Production and Engineering of GD2-Targeted, Receptor Modified T Cells (GD2CART) for Osteosarcoma or Neuroblastoma to Increase Systemic Tumor ExposureStatus: , Estimated PCD: 2040-12-31